Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 12/2014

01-12-2014 | Original Article

Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction

Authors: Marie-Cristine Kuehnle, Sebastian Attig, Cedrik M. Britten, Henning Schulze-Bergkamen, Florian Lordick, Goetz von Wichert, Peter Thuss-Patience, Alexander Stein, Martin Schuler, Florian Bassermann, Ugur Sahin, Özlem Türeci

Published in: Cancer Immunology, Immunotherapy | Issue 12/2014

Login to get access

Abstract

Immunotherapeutic approaches are emerging as promising new treatment options for patients with solid cancers. The host immune system in cancer patients is dysfunctional due to a number of reasons. The level of immunosuppression is variable at the time of diagnosis and depends on the particular cancer entity, stage, and prior anti-cancer therapies. For many cancer entities, the immune alterations of the respective patient population have not been further characterized even though a patient’s immunophenotype may be prognostic for the course of the disease or predictive for clinical/biological response to immunotherapy. In this study, we used flow cytometry to determine the phenotype of peripheral blood mononuclear cells (PBMCs) from 30 patients with heavily pre-treated, advanced adenocarcinoma of the stomach and gastro-esophageal junction. The frequencies and activation status of relevant immune effector populations were determined in PBMCs and compared to those of healthy individuals. This report provides comprehensive immune phenotyping data of a patient population with a high medical need.
Appendix
Available only for authorised users
Literature
7.
go back to reference Bibeau F, Lopez-Crapez E, Di Fiore F et al (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27:1122–1129. doi:10.1200/JCO.2008.18.0463 PubMedCrossRef Bibeau F, Lopez-Crapez E, Di Fiore F et al (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27:1122–1129. doi:10.​1200/​JCO.​2008.​18.​0463 PubMedCrossRef
8.
go back to reference Cartron G, Dacheux L, Salles G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754–758PubMedCrossRef Cartron G, Dacheux L, Salles G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754–758PubMedCrossRef
9.
go back to reference Musolino A, Naldi N, Bortesi B et al (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789–1796. doi:10.1200/JCO.2007.14.8957 PubMedCrossRef Musolino A, Naldi N, Bortesi B et al (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789–1796. doi:10.​1200/​JCO.​2007.​14.​8957 PubMedCrossRef
11.
go back to reference Braun DP, Harris JE (1981) Relationship of leukocyte numbers, immunoregulatory cell function, and phytohemagglutinin responsiveness in cancer patients. J Natl Cancer Inst 67:809–814PubMed Braun DP, Harris JE (1981) Relationship of leukocyte numbers, immunoregulatory cell function, and phytohemagglutinin responsiveness in cancer patients. J Natl Cancer Inst 67:809–814PubMed
12.
go back to reference Hong WS, Kim CM, Lee JO, Kang TW, Yun TK, Kim CY (1990) Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy. Jpn J Clin Oncol 20:87–93PubMed Hong WS, Kim CM, Lee JO, Kang TW, Yun TK, Kim CY (1990) Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy. Jpn J Clin Oncol 20:87–93PubMed
14.
go back to reference Dillman RO, Koziol JA, Zavanelli MI et al (1984) Immunoincompetence in cancer patients. Assessment by in vitro stimulation tests and quantification of lymphocyte subpopulations. Cancer 53:1484–1491PubMedCrossRef Dillman RO, Koziol JA, Zavanelli MI et al (1984) Immunoincompetence in cancer patients. Assessment by in vitro stimulation tests and quantification of lymphocyte subpopulations. Cancer 53:1484–1491PubMedCrossRef
15.
go back to reference Kaszubowski PA, Husby G, Tung KS, Williams RC Jr (1980) T-lymphocyte subpopulations in peripheral blood and tissues of cancer patients. Cancer Res 40:4648–4657PubMed Kaszubowski PA, Husby G, Tung KS, Williams RC Jr (1980) T-lymphocyte subpopulations in peripheral blood and tissues of cancer patients. Cancer Res 40:4648–4657PubMed
17.
go back to reference Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150. doi:10.1200/JCO.2005.05.2308 PubMedCrossRef Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150. doi:10.​1200/​JCO.​2005.​05.​2308 PubMedCrossRef
19.
go back to reference Schuler MH, Zvirbule Z, Lordick F et al (2013) Safety, tolerability and efficacy of the first-in-class antibody IMAB362 as evaluated in a phase I single dose and phase II multiple dose study in patients with advanced gastroesophageal adenocarcinomas. J Clin Oncol 31:Suppl; abstr 4080 Schuler MH, Zvirbule Z, Lordick F et al (2013) Safety, tolerability and efficacy of the first-in-class antibody IMAB362 as evaluated in a phase I single dose and phase II multiple dose study in patients with advanced gastroesophageal adenocarcinomas. J Clin Oncol 31:Suppl; abstr 4080
21.
go back to reference Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606–612PubMed Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606–612PubMed
24.
go back to reference Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949. doi:10.1038/nm1093 PubMedCrossRef Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949. doi:10.​1038/​nm1093 PubMedCrossRef
27.
29.
go back to reference Walter S, Weinschenk T, Stenzl A et al (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254–1261. doi:10.1038/nm.2883 PubMedCrossRef Walter S, Weinschenk T, Stenzl A et al (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254–1261. doi:10.​1038/​nm.​2883 PubMedCrossRef
30.
31.
go back to reference Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 61:4756–4760PubMed Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 61:4756–4760PubMed
32.
go back to reference Almand B, Clark JI, Nikitina E et al (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689PubMedCrossRef Almand B, Clark JI, Nikitina E et al (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689PubMedCrossRef
34.
go back to reference Pohla H, Buchner A, Stadlbauer B et al (2013) High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination. Mol Med 18:1499–1508. doi:10.2119/molmed.2012.00221 PubMed Pohla H, Buchner A, Stadlbauer B et al (2013) High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination. Mol Med 18:1499–1508. doi:10.​2119/​molmed.​2012.​00221 PubMed
36.
go back to reference Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW (2011) Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 60:1419–1430. doi:10.1007/s00262-011-1028-0 PubMedCentralPubMedCrossRef Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW (2011) Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 60:1419–1430. doi:10.​1007/​s00262-011-1028-0 PubMedCentralPubMedCrossRef
38.
go back to reference Coca S, Perez-Piqueras J, Martinez D et al (1997) The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79:2320–2328PubMedCrossRef Coca S, Perez-Piqueras J, Martinez D et al (1997) The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79:2320–2328PubMedCrossRef
40.
go back to reference Lanier LL, Ruitenberg J, Bolhuis RL, Borst J, Phillips JH, Testi R (1988) Structural and serological heterogeneity of gamma/delta T cell antigen receptor expression in thymus and peripheral blood. Eur J Immunol 18:1985–1992. doi:10.1002/eji.1830181218 PubMedCrossRef Lanier LL, Ruitenberg J, Bolhuis RL, Borst J, Phillips JH, Testi R (1988) Structural and serological heterogeneity of gamma/delta T cell antigen receptor expression in thymus and peripheral blood. Eur J Immunol 18:1985–1992. doi:10.​1002/​eji.​1830181218 PubMedCrossRef
43.
go back to reference Tokuyama H, Hagi T, Mattarollo SR et al (2008) V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—rituximab and trastuzumab. Int J Cancer 122:2526–2534. doi:10.1002/ijc.23365 PubMedCrossRef Tokuyama H, Hagi T, Mattarollo SR et al (2008) V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—rituximab and trastuzumab. Int J Cancer 122:2526–2534. doi:10.​1002/​ijc.​23365 PubMedCrossRef
Metadata
Title
Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction
Authors
Marie-Cristine Kuehnle
Sebastian Attig
Cedrik M. Britten
Henning Schulze-Bergkamen
Florian Lordick
Goetz von Wichert
Peter Thuss-Patience
Alexander Stein
Martin Schuler
Florian Bassermann
Ugur Sahin
Özlem Türeci
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 12/2014
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-014-1596-x

Other articles of this Issue 12/2014

Cancer Immunology, Immunotherapy 12/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine